Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 2.009
Filter
1.
Front Public Health ; 10: 1027782, 2022.
Article in English | MEDLINE | ID: mdl-36544792

ABSTRACT

Background: In general, medical staff who work in nuclear medicine should be entirely safe in their professional environment. Nevertheless, we already know that the working environment of the nuclear medicine staff is not completely safe due to the handling of high amounts of radionuclides for diagnostic and therapy applications, which is especially relevant for 131I (as a non-sealed source). Purpose: The goal of this study was to assess the inhaled 131I thyroid dose in nuclear medicine workers and to introduce a simple method for internal exposure monitoring. Methods: Using 2-IN*2-in NaI (Tl) scintillation spectrometer and its supporting software (InSpector Maintenance Utility and Genie 2000), from 2019 to 2021, internal thyroid irradiation monitoring, an internal thyroid irradiation monitoring investi A NaI (Tl) scintillation spectrometer and its sugation was carried out for 3 consecutive years, between 2019 and 2021, in staff members of nuclear medicine departments engaged with iodine therapy. Results: 131I activity was found highest in the thyroid of nuclear medicine workers involved with the manual packaging and delivery of the radioisotope, while it was not detected in staff members involved with the automatic packaging and drug delivery. The activity range was found to be 30.00 ± 6.60-6070.00 ± 1335.40 Bq for the exposed personnel, and the estimated dose was 0.05-6.77 mSv. In 2021, three workers had an annual equivalent dose above 5 mSv. Conclusion: By monitoring the thyroid 131I in staff members of the nuclear medicine department, it was found that there are 131I internal occupational exposure risks. The best solution is automatic packaging and drug delivery.


Subject(s)
Nuclear Medicine , Humans , Thyroid Gland/chemistry , Thyroid Gland/radiation effects , Radiation Dosage , Iodine Radioisotopes/therapeutic use , Iodine Radioisotopes/analysis
2.
Sci Rep ; 12(1): 21754, 2022 12 16.
Article in English | MEDLINE | ID: mdl-36526648

ABSTRACT

Nuclear plant accidents can be a risk for thyroid cancer due to iodine radioisotopes. Near the Fukushima Daiichi nuclear power plant, cattle were exposed to radiation after the accident occurred in May 2011. Here we estimated the total radiation exposure to cattle thyroid and its effects on thyroid function. Until October 2016, the estimated external exposure dose in Farm A was 1416 mGy, while internal exposure dose of 131I, 134Cs, and 137Cs were 85, 8.8, and 9.7 mGy in Farm A and 34, 0.2, and 0.3 mGy in Farm B, respectively. The exposed cattle had thyroid with relatively lower weight and lower level of stable iodine, which did not exhibit any pathological findings. Compared with the control, the plasma level of thyroid-stimulating hormone (TSH) was higher in Farm A cattle born before the accident, while the plasma thyroxine (T4) was higher in Farm A cattle born after the accident, suggesting that exposed cattle showed slight hyperactivation of the thyroid gland. In addition, Farm A cattle have higher level of cortisol, one of the anterior pituitary gland-derived hormones. However, we did not observe a causal relationship between the radiation exposure and cattle thyroid.


Subject(s)
Fukushima Nuclear Accident , Radiation Exposure , Cattle , Animals , Nuclear Power Plants , Thyroid Gland/radiation effects , Iodine Radioisotopes/adverse effects , Iodine Radioisotopes/analysis , Radiation Exposure/adverse effects , Japan/epidemiology , Radiation Dosage
3.
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi ; 40(10): 733-736, 2022 Oct 20.
Article in Chinese | MEDLINE | ID: mdl-36348552

ABSTRACT

Objective: To investigate the effect of low-dose X-ray ionizing radiation on thyroid function of radiation workers. Methods: From January to December 2021, a total of 1039 medical workers in some tertiary hospitals in Wuhan were selected as the survey subjects, of which 518 radiation workers were selected as the exposure group, and 521 non-radiation workers were selected as the control group. The general conditions of the two groups were collected, and 5 indicators of thyroid function were measured, including total thyroxine (TT(4)) , total triiodothyronine (TT(3)) , free triiodothyronine (FT(3)) , thyroid stimulating hormone (TSH) , and free thyroxine (FT(4)) . The annual cumulative dose of ionizing radiation exposure in the exposure group was collected. Pearson χ(2) test and independent sample t test were used to compare the general conditions, 5 indicators of thyroid function and abnormal rate between the two groups. Linear regression model was used to analyze the correlation between the annual cumulative dose and 5 indicators of thyroid function in the exposure group. Binary logistic regression was used to analyze the influencing factors of thyroid dysfunction in the exposure group. Results: The TT(4) levels of the workers in the control group and the exposure group were (7.95±1.07) µg/dl and (8.26±1.41) µg/dl, respectively, and the FT(4) levels were (16.33±2.19) pmol/L and (17.15±2.42) pmol/L, respectively, the rate of thyroid dysfunction was 4.80% (25/521) and 8.49% (44/518) , and the above differences were statistically significant (P<0.05) . Linear regression analysis showed that the annual cumulative dose of the exposure group was significantly correlated with TT(4), TT(3), FT(4), and TSH (P<0.05) . For every 1 mSv increase in the annual cumulative dose, TT(4) increased by 1.661 µg/dl, FT(4) increased by 1.422 pmol/L, TT(3) decreased by 0.113 ng/ml, and TSH decreased by 0.731 µIU/ml. Binary logistic regression analysis showed that the older the radiation workers, the higher the risk of thyroid dysfunction (OR=1.080, 95% CI: 1.016-1.148, P=0.013) ; the greater the annual cumulative dose, the higher the risk of thyroid dysfunction (OR=6.400, 95%CI: 1.796-22.811, P=0.004) . Conclusion: The annual cumulative dose of low-dose X-ray ionizing radiation is positively correlated with thyroid function TT(4) and FT(4) of radiation workers, and negatively correlated with TT(3) and TSH; the greater the age and annual cumulative dose, the higher the risk of thyroid dysfunction.


Subject(s)
Thyroxine , Triiodothyronine , Humans , Thyroid Gland/radiation effects , X-Rays , Thyrotropin , Radiation, Ionizing
4.
Article in English | MEDLINE | ID: mdl-35534405

ABSTRACT

OBJECTIVE: The purpose of this study was to evaluate the impact of thyroid gland shielding on radiation doses in dental cone beam computed tomography (CBCT) with small and medium fields of view (FOVs). STUDY DESIGN: Six CBCT protocols were investigated by exposing an adult anthropomorphic male phantom head without and with thyroid shielding, using 4 small (4 × 5 cm) and 2 medium (10 × 6 cm) FOVs. Twenty metal oxide semiconductor field-effect transistor dosimeters were placed in the phantom head to measure absorbed doses and calculate equivalent doses at 11 sites. Effective doses were calculated based on the tissue weighting factors in International Commission on Radiological Protection Publication 103. The data were analyzed using the independent samples t test. RESULTS: Thyroid gland shielding led to significant equivalent dose reductions in many tissues for all protocols. Equivalent dose reductions to the thyroid were significant in all 6 protocols (P ≤ .037). Significant reduction depended on the FOV and ranged between 24.5% and 42.6% for the thyroid gland and 4.9% and 34.5% for other tissues and organs. Effective doses were significantly lower in all protocols (P ≤ .016). CONCLUSIONS: Thyroid gland shielding protects the thyroid gland and other organs and should be utilized with all CBCT examinations where feasible.


Subject(s)
Thermoluminescent Dosimetry , Thyroid Gland , Adult , Cone-Beam Computed Tomography/methods , Humans , Male , Phantoms, Imaging , Radiation Dosage , Thermoluminescent Dosimetry/methods , Thyroid Gland/radiation effects
5.
Sci Rep ; 12(1): 2107, 2022 02 08.
Article in English | MEDLINE | ID: mdl-35136135

ABSTRACT

131I is used clinically for therapy, and may be released during nuclear accidents. After the Chernobyl accident papillary thyroid carcinoma incidence increased in children, but not adults. The aims of this study were to compare 131I irradiation-dependent differences in RNA and protein expression in the thyroid and plasma of young and adult rats, and identify potential age-dependent biomarkers for 131I exposure. Twelve young (5 weeks) and twelve adult Sprague Dawley rats (17 weeks) were i.v. injected with 50 kBq 131I (absorbed dose to thyroid = 0.1 Gy), and sixteen unexposed age-matched rats were used as controls. The rats were killed 3-9 months after administration. Microarray analysis was performed using RNA from thyroid samples, while LC-MS/MS analysis was performed on proteins extracted from thyroid tissue and plasma. Canonical pathways, biological functions and upstream regulators were analysed for the identified transcripts and proteins. Distinct age-dependent differences in gene and protein expression were observed. Novel biomarkers for thyroid 131I exposure were identified: (PTH), age-dependent dose response (CA1, FTL1, PVALB (youngsters) and HSPB6 (adults)), thyroid function (Vegfb (adults)). Further validation using clinical samples are needed to explore the role of the identified biomarkers.


Subject(s)
Biomarkers/blood , Iodine Radioisotopes/adverse effects , Thyroid Gland/radiation effects , Age Factors , Animals , Gene Expression Profiling , Rats, Sprague-Dawley , Thyroid Gland/metabolism , Thyroid Gland/pathology , Thyroid Hormones/blood , Time Factors
6.
J Clin Endocrinol Metab ; 107(2): e448-e457, 2022 01 18.
Article in English | MEDLINE | ID: mdl-34555150

ABSTRACT

Radioactive iodine has been considered a safe and effective therapeutic option for hyperthyroidism secondary to Graves disease and autonomously functioning thyroid nodules since the mid-20th century. The question of whether I-131 at the doses used for hyperthyroidism might increase the risk of cancer has been investigated in a number of observational cohort studies over the years, with the preponderance of evidence being reassuring as to its safety. In particular, the 1998 Cooperative Thyrotoxicosis Therapy Follow-up Study (CTTFUS) has been widely cited as compelling evidence that I-131 is safe in hyperthyroidism therapy with respect to carcinogenesis. However, in 2019, a study by Kitahara and colleagues re-analyzed the CTTFUS cohort, extending the follow-up time and applying a novel dosimetric model for estimating tissue absorbed doses of radiation. This new analysis concluded that radioactive iodine was associated with an increased risk for mortality from overall cancer, breast cancer, and non-breast solid cancers. Reaction to this study was vociferous and particularly negative in the nuclear medicine literature. This mini-review was inspired by the 2019 CTTFUS controversy, and it is intended to provide the necessary context for clinicians to provide nuanced advice to their patients on the subject. To that end, the pre-2019 literature is surveyed, the 2019 CTTFUS study and a 2020 follow-up are discussed, and lessons from the literature and critical commentaries are considered.


Subject(s)
Hyperthyroidism/therapy , Iodine Radioisotopes/adverse effects , Neoplasms, Radiation-Induced/epidemiology , Thyroid Gland/radiation effects , Thyroid Neoplasms/epidemiology , Dose-Response Relationship, Radiation , Humans , Incidence , Neoplasms, Radiation-Induced/pathology , Observational Studies as Topic , Radiometry , Risk Assessment/statistics & numerical data , Thyroid Gland/pathology , Thyroid Neoplasms/etiology , Thyroid Neoplasms/pathology
7.
Probl Radiac Med Radiobiol ; 26: 188-198, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34965548

ABSTRACT

OBJECTIVE: To describe the status and results of thyroid disease screening and assessment of reliability of radiationthyroid doses in the Belarusian in utero cohort of 2,965 individuals exposed to Chernobyl (Chornobyl) fallout. MATERIALS AND METHODS: Thyroid screening examinations are currently underway including thyroid palpation by anendocrinologist, ultrasonographic examination by an ultrasonographer and analysis of blood samples for diagnosisof hypo- and hyperthyroidism, autoimmune thyroiditis, thyroid function tests (thyroid-stimulating hormone [TSH],thyroxine [T4], thyroid peroxidase antibody [anti-TPO], and thyroglobulin antibodies [anti-TG]). Reliability of (i)information from 780 pairs of questionnaires obtained during the first and second interviews of the mothers and (ii)thyroid doses, which were calculated for the cohort members using this information, is evaluated. RESULTS: As of 15 August 2021, 1,267 in utero exposed study subjects had been screened. A single thyroid nodule wasdiagnosed in 167 persons (13.2 % of the total) and multiple thyroid nodules in 101 persons (8.0 %): 189 (14.9 %)persons had nodules detected for the first time at the screening while 79 (6.2 %) persons had nodules detected pre-viously (pre-screening nodules). Fifty-nine out of 268 subjects (22.0 %) with a suspicious thyroid nodule werereferred to fine needle aspiration biopsy, and among them 33 (55.9 %) were biopsied. Reasonable agreement wasobserved for modelqbased doses calculated for the Belarusian in utero cohort members using data from the two inter-views (Spearman's rank-correlation coefficient rs = 0.74, p < 0.001), while measurementqbased doses yielded almost per-fect agreement (rs = 0.99, p < 0.001). CONCLUSIONS: During the thyroid screening, at least one thyroid nodule was identified in 268 of 1,267 (21.2 %) inutero exposed cohort members. Seven thyroid cancer cases were identified in the cohort, including 5 pre-screeningcases and 2 cases detected during the screening. Ongoing research on this unique cohort will provide importantinformation on adverse health effects following prenatal and postnatal exposure to radioiodine and radiocesium iso-topes, for which available epidemiological data are scant.


Subject(s)
Chernobyl Nuclear Accident , Fetus/radiation effects , Pregnant Women , Radiation Dosage , Radioactive Fallout/adverse effects , Thyroid Gland/physiopathology , Thyroid Gland/radiation effects , Thyroid Nodule/physiopathology , Adult , Cohort Studies , Female , Humans , Infant, Newborn , Longitudinal Studies , Male , Maternal Exposure/statistics & numerical data , Neoplasms, Radiation-Induced/epidemiology , Pregnancy , Prenatal Exposure Delayed Effects , Reproducibility of Results , Republic of Belarus , Thyroid Nodule/epidemiology , Thyroid Nodule/etiology , Ukraine
8.
Probl Radiac Med Radiobiol ; 26: 297-308, 2021 Dec.
Article in English, Ukrainian | MEDLINE | ID: mdl-34965556

ABSTRACT

OBJECTIVE: to establish the relationship between quantitative and qualitative parameters of peripheral blood cells(lymphocytes, neutrophilic granulocytes, monocytes, platelets) depending on the type of somatic diseases andannual internal radiation doses from 137Cs in children - residents of radiologically contaminated territories in thelate period after the Chornobyl Nuclear Power Plant (ChNPP) accident. MATERIALS AND METHODS: There were 175 children included in the study comprising residents of radiologically con-taminated territories (n = 79) aged from 4 to 18 years. Annual internal radiation doses in children from 137Cs rangedfrom 0.004 to 0.067 mSv. Certain blood parameters were assessed in a comparative mode in children having got theradiation doses up to 0.01 mSv and higher. The comparison group (n = 96) included children living in settlementsnot attributed to the radiologically contaminated ones. Incidence and type of somatic diseases and its impact onquantitative and qualitative changes in blood parameters (i.e. lymphocyte, neutrophilic granulocyte, monocyte, andplatelet count) were studied. The cell size, state of nucleus, membranes and cytoplasm, signs of proliferative anddegenerative processes were taken into account. RESULTS: Incidence and type of somatic diseases in children did not depend on the annual internal radiation dose.Number of cases of monocytosis was significantly higher among the children exposed to ionizing radiation than inthe comparison group (16.6 % vs. 7.3 %). There were, however, no correlation between these changes and radiationdoses. Number of activated blood monocytes with cytoplasmic basophilia and residues of nucleoli in nuclei washigher in individuals with internal radiation doses > 0.01 mSv. A direct correlation between the qualitative param-eters of monocytes and internal radiation doses was established (rs = 0.60; р < 0.001), as well as a direct correlationof different strength between qualitative parameters of blood cells, indicating their unidirectional pattern depend-ing on the somatic morbid conditions. Regardless of annual internal radiation dose, there was an increase in thenumber of degenerative and aberrant cells vs. the comparison group (р < 0.05), which could be due to the role ofnon-radiation factors. CONCLUSIONS: Results of the assessment of quantitative and qualitative parameters of peripheral blood cells reflect-ed the state of morbid conditions in children and are of a diagnostic value. The identified dose-dependent changesin monocyte lineage of hematopoiesis may be the markers of impact of long-term radionuclide incorporation withfood in children living in environmentally unfavorable conditions after the ChNPP accident.


Subject(s)
Blood/radiation effects , Chernobyl Nuclear Accident , Hematologic Diseases/blood , Hematologic Diseases/physiopathology , Radiation Exposure/adverse effects , Radiation Injuries/blood , Radiation, Ionizing , Thyroid Gland/radiation effects , Adolescent , Child , Child, Preschool , Female , Humans , Male , Radiation Injuries/physiopathology , Radiation Monitoring/statistics & numerical data , Ukraine/epidemiology
9.
Acta Otolaryngol ; 141(11): 1022-1026, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34738883

ABSTRACT

BACKGROUND: Hypothyroidism is a common adverse event after radiotherapy for head and neck tumors and the incidence need to be re-evaluated because of using intensity-modulated radiotherapy (IMRT). AIMS/OBJECTIVES: Confirm the dose-volume effect of IMRT for pharyngeal cancer on hypothyroidism. MATERIALS AND METHODS: This was a retrospective analysis of patients underwent IMRT for pharyngeal cancer from June 2011 to May 2018. Patients were classified into group A (thyroid stimulating hormone (TSH) <5µU/ml), group B (5< =TSH < 10), and group C (10< =TSH) based on TSH over 36 months post-radiation. Radiation dose, thyroid volume, and the proportion of the thyroid that received X Gy or greater (Vx) were measured. RESULTS: Fifty-two patients were included in this work. Hypothyroidism developed in 33/52 (63%) patients, 13 in group B and 20 in group C. The mean radiation dose to the thyroid was 49.4 Gy and the median time until hypothyroidism was 39 months after irradiation. Hypothyroidism was significantly related to neck dissection (ND) and radiation dose to the thyroid. Patients whose thyroid received 45 Gy or more (V45) >67% had a significantly higher incidence of hypothyroidism. CONCLUSIONS AND SIGNIFICANCE: Patients with pharyngeal cancer who had ND and V45 to the thyroid >67% are at risk of hypothyroidism.


Subject(s)
Hypothyroidism/etiology , Pharyngeal Neoplasms/radiotherapy , Radiotherapy, Intensity-Modulated/adverse effects , Squamous Cell Carcinoma of Head and Neck/radiotherapy , Thyroid Gland/radiation effects , Aged , Combined Modality Therapy , Dose-Response Relationship, Radiation , Female , Humans , Incidence , Male , Middle Aged , Neck Dissection/adverse effects , Pharyngeal Neoplasms/surgery , Radiation Injuries , Radiotherapy Dosage , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck/surgery
10.
Thyroid ; 31(12): 1829-1838, 2021 12.
Article in English | MEDLINE | ID: mdl-34598656

ABSTRACT

Background: Patients with Graves' disease are commonly treated with radioiodine. There remains controversy over whether the aim of treatment should be to achieve euthyroidism or hypothyroidism, and whether treatments should be administered with standard levels of radioactivity or personalized according to the radiation absorbed doses delivered to the thyroid. The aim of this review was to investigate whether a relationship exists between radiation absorbed dose and treatment outcome. Methods: A systematic review and meta-analysis of all reports published before February 13, 2020, were performed using PubMed, Web of Science, OVID MEDLINE, and Embase. Proportion of patients achieving nonhyperthyroid status was the primary outcome. Secondary outcomes were proportion of patients who were specifically euthyroid or hypothyroid. A random-effects meta-analysis of proportions was performed for primary and secondary outcomes, and the impact of the radiation absorbed dose on treatment outcome was assessed through meta-regression. The study is registered with PROSPERO (CRD42020175010). Results: A total of 1122 studies were identified of which 15, comprising 2303 Graves' disease patients, were eligible for the meta-analysis. A strong association was found between radiation absorbed dose and nonhyperthyroid and hypothyroid outcomes (odds ratio [OR] = 1.11 [95% confidence interval {CI} 1.08-1.14] and OR = 1.09 [CI 1.06-1.12] per 10 Gy increase). Higher rates of euthyroid outcome were found for radiation absorbed doses within the range 120-180 Gy when compared with outside this range (n = 1172, OR = 2.50 [CI 1.17-5.35], p = 0.018). A maximum euthyroid response of 38% was identified at a radiation absorbed dose of 128 Gy. Conclusions: The presented radiation absorbed dose-response relationships can facilitate personalized treatment planning for radioiodine treatment of patients with Graves' disease. Further studies are required to determine how patient-specific covariates can inform personalized treatments.


Subject(s)
Graves Disease/radiotherapy , Iodine Radioisotopes/pharmacokinetics , Radiotherapy Dosage , Thyroid Gland/radiation effects , Humans , Iodine Radioisotopes/therapeutic use
11.
J Cancer Res Ther ; 17(4): 1025-1030, 2021.
Article in English | MEDLINE | ID: mdl-34528559

ABSTRACT

CONTEXT: Majority of the head-and-neck cancers are locoregionally advanced at the time of diagnosis. Hence, radiotherapy (RT) portals will invariably cover the whole neck and thus, the thyroid gland which may lead to its dysfunction. AIMS: The purpose of this study is to identify the functional and biochemical changes in the thyroid gland following RT to the neck using single-photon emission computed tomography-computed tomography (SPECT-CT) and thyroid function tests (TFTs). SUBJECTS AND METHODS: In this prospective study, 45 patients of the head-and-neck cancer, receiving RT with or without chemotherapy were investigated. Baseline TFTs and thyroid scans (on SPECT-CT) were done, and the same were repeated at the completion of RT, at 3 and 6 months. RESULTS: All patients received a minimum of 30 Gy to the whole neck. Baseline TFTs and thyroid scans were normal. None of them developed hypothyroidism clinical or subclinical (C/S) at the completion of RT. Six patients developed hypothyroidism (four subclinical, two clinical) at 3 months of the completion of treatment. At 6 months of follow-up 14 patients (31.1%) developed hypothyroidism (ten subclinical, four clinical) with P≤ 0.01. All patients having clinical or subclinical hypothyroidism had decreased uptake on thyroid scan. Patients having decreased uptake on thyroid scan only, with normal TFTs and no symptoms of hypothyroidism were zero at the completion of RT, 1 at 3 months follow-up, and seven at 6 months follow-up. CONCLUSIONS: Hypothyroidism (C/S) is an under-recognized but significant complication of therapeutic doses of RT to the neck. In our study, we recognized hypothyroidism as early as 3 months following the completion of RT. Hence, tests to evaluate functional and biochemical changes in the thyroid gland should be instituted as early as 3 months following RT.


Subject(s)
Head and Neck Neoplasms/radiotherapy , Hypothyroidism/pathology , Radiation Injuries/pathology , Radiotherapy/adverse effects , Squamous Cell Carcinoma of Head and Neck/radiotherapy , Thyroid Gland/pathology , Adult , Aged , Aged, 80 and over , Chemoradiotherapy , Female , Follow-Up Studies , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/pathology , Humans , Hypothyroidism/etiology , Male , Middle Aged , Prognosis , Prospective Studies , Radiation Injuries/etiology , Radiotherapy Dosage , Squamous Cell Carcinoma of Head and Neck/drug therapy , Squamous Cell Carcinoma of Head and Neck/pathology , Thyroid Function Tests , Thyroid Gland/radiation effects
12.
Cancer Radiother ; 25(8): 771-778, 2021 Dec.
Article in French | MEDLINE | ID: mdl-34175226

ABSTRACT

PURPOSE: The purpose of this study was to assess the efficacy in terms of neck failure of an initial neck dissection before definitive chemoradiotherapy in N2-3 oropharyngeal squamous cell carcinomas, as well as the dosimetric impact and the acute and delayed morbidity of this approach. MATERIALS AND METHODS: All patients consecutively treated between 2009 and 2018 with definitive chemoradiotherapy using intensity-modulated conformal radiotherapy (IMRT) for a histologically proven N2-3 oropharyngeal squamous cell carcinomas were retrospectively included. The therapeutic approach consisted of induction chemotherapy, followed by cisplatine-based chemoradiotherapy preceded or not by neck dissection. Neck dissection was discussed on a case-by-case basis in a dedicated multidisciplinary tumour board for patients with a dissociated response to induction chemotherapy, defined as a better response on the primary than on the node. Chemoradiotherapy without neck dissection was systematically performed in case of a major lymph node response to induction chemotherapy (decrease in size of 90% or more). Intensity-modulated radiotherapy using a simultaneous-integrated boost delivered 70Gy in 35 fractions on macroscopic tumour volumes, 63Gy on intermediate-risk levels or extra-nodal extension and 54Gy on prophylactic lymph node areas. RESULTS: Two groups were constituted: 47 patients without an initial neck dissection (62.7%), and 28 patients with a neck dissection prior to definitive chemoradiotherapy (37.3%). Initial patient characteristics were not statistically different between the two groups. The median follow-up was 60.1months (range: 3.2-119months). Incidence of neck failure was higher in patients without neck dissection (P=0.015). The neck failure rate at 5years was 19.8% (95% confidence interval: 7.4-30.6%; P=0.015) without neck dissection versus 0% following neck dissection. All lymph node failures occurred in the planned target volume at 70Gy. Upfront neck dissection suggested a decrease in the mean dose received by the homolateral parotid gland (P=0.01), mandible (P=0.02), and thyroid gland (P=0.02). Acute toxicity of chemoradiotherapy after neck dissection suggested a reduction in grade≥3 adverse events (P=0.04), early discontinuation of concomitant chemotherapy (P=0.009) and feeding tube-dependence (P=0.008) in univariate analysis. During follow-up, there was no difference between the two groups in terms of xerostomia, dysgeusia, dysphagia or gastrostomy dependence in univariate analysis. CONCLUSION: Neck dissection prior to definitive chemoradiotherapy in N2-3 oropharyngeal squamous cell carcinoma was associated with high neck control without additional mid and long-term morbidity.


Subject(s)
Chemoradiotherapy/methods , Neck Dissection , Oropharyngeal Neoplasms/therapy , Radiotherapy, Intensity-Modulated , Squamous Cell Carcinoma of Head and Neck/therapy , Adult , Aged , Aged, 80 and over , Chemoradiotherapy/adverse effects , Cisplatin/therapeutic use , Combined Modality Therapy/methods , Deglutition Disorders/epidemiology , Dose Fractionation, Radiation , Dysgeusia/epidemiology , Female , Follow-Up Studies , Humans , Induction Chemotherapy , Lymphatic Metastasis , Male , Mandible/radiation effects , Middle Aged , Neck Dissection/adverse effects , Organs at Risk/radiation effects , Oropharyngeal Neoplasms/mortality , Oropharyngeal Neoplasms/pathology , Parotid Gland/radiation effects , Radiotherapy Dosage , Radiotherapy, Intensity-Modulated/adverse effects , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck/mortality , Squamous Cell Carcinoma of Head and Neck/pathology , Thyroid Gland/radiation effects , Xerostomia/epidemiology
13.
J Radiat Res ; 62(Supplement_1): i78-i87, 2021 May 05.
Article in English | MEDLINE | ID: mdl-33978177

ABSTRACT

Although the association between radiation exposure and thyroid carcinogenesis is epidemiologically evident, 'true' radiation-induced cancers cannot be identified from biological evidence of radiation-associated cases. To assess the individual risk for thyroid cancer due to radiation exposure, we aimed to identify biomarkers that are specifically altered during thyroid carcinogenesis after irradiation in a time-dependent manner in an animal model. Thyroid glands were obtained from rats (n = 175) at 6-16 months after local X-ray (0.1-4 Gy) irradiation of the neck at 7 weeks of age. The gene expression profile in thyroid glands was comprehensively analyzed using RNA microarray. Subsequently, the expression levels of the genes of interest were verified using droplet digital PCR (ddPCR). The expression level of candidate genes as biomarkers for irradiated thyroid was examined in a randomized, controlled, double-blind validation study (n = 19) using ddPCR. The incidence of thyroid cancer increased in a dose- and time-dependent manner and was 33% at 16 months after irradiation with 4 Gy. The Ki-67 labeling index in non-tumorous thyroid was significantly higher in the exposed group than in the control. Comprehensive analysis identified radiation-dependent alteration in 3329 genes. Among them, ddPCR revealed a stepwise increase in CDKN1A expression from early pre-cancerous phase in irradiated thyroid compared to that in the control. The irradiated thyroids were accurately distinguished (positive predictive value 100%, negative predictive value 69%) using 11.69 as the cut-off value for CDKN1A/ß-actin. Thus, CDKN1A expression can be used as a biomarker for irradiated thyroid glands at the pre-cancerous phase.


Subject(s)
Carcinogenesis/genetics , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Neoplasms, Radiation-Induced/genetics , Thyroid Neoplasms/genetics , Animals , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Carcinogenesis/pathology , Male , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats, Wistar , Reproducibility of Results , Thyroid Gland/pathology , Thyroid Gland/radiation effects , Thyroid Neoplasms/pathology
14.
J Radiat Res ; 62(Supplement_1): i64-i70, 2021 May 05.
Article in English | MEDLINE | ID: mdl-33978183

ABSTRACT

The complex disaster of the Great East Japan Earthquake and the Fukushima nuclear accident caused concern about their various health impacts. Many types of intervention are desired as a countermeasure, depending on the phase of the disaster cycle. The importance of developing and applying codes of conduct has recently been emphasized for post-disaster investigations. Thyroid examination as a type of cancer screening survey was launched from October 2011 after the Fukushima nuclear accident as part of the Fukushima Health Management Survey. In this article, we reviewed the results of three rounds of thyroid examination from 2011 to 2018, and summarized the points to consider in the health survey conducted after the Fukushima nuclear accident. Large-scale mass screening by ultrasound thyroid examination resulted in many cancer diagnoses, >200 cases from a large reservoir of thyroid cancer that goes mainly unnoticed without screening. To prevent the harms of such over-diagnosis, we should be aware of the disadvantage of mass-screening based on the expected natural history of thyroid cancer. A change in strategy from mass-screening to individual monitoring is urgently needed according to international recommendations that are opposed to thyroid ultrasound cancer screening even after a nuclear disaster. To guarantee autonomy and informed choice on post-disaster disease monitoring for residents in a disaster-zone, it is important to set protocol participation and on a voluntary code of conduct basis.


Subject(s)
Fukushima Nuclear Accident , Radiation Monitoring , Dose-Response Relationship, Radiation , Health Surveys , Humans , Thyroid Gland/radiation effects , Thyroid Neoplasms/pathology
15.
Science ; 372(6543)2021 05 14.
Article in English | MEDLINE | ID: mdl-33888599

ABSTRACT

The 1986 Chernobyl nuclear power plant accident increased papillary thyroid carcinoma (PTC) incidence in surrounding regions, particularly for radioactive iodine (131I)-exposed children. We analyzed genomic, transcriptomic, and epigenomic characteristics of 440 PTCs from Ukraine (from 359 individuals with estimated childhood 131I exposure and 81 unexposed children born after 1986). PTCs displayed radiation dose-dependent enrichment of fusion drivers, nearly all in the mitogen-activated protein kinase pathway, and increases in small deletions and simple/balanced structural variants that were clonal and bore hallmarks of nonhomologous end-joining repair. Radiation-related genomic alterations were more pronounced for individuals who were younger at exposure. Transcriptomic and epigenomic features were strongly associated with driver events but not radiation dose. Our results point to DNA double-strand breaks as early carcinogenic events that subsequently enable PTC growth after environmental radiation exposure.


Subject(s)
Chernobyl Nuclear Accident , Mutation , Neoplasms, Radiation-Induced/genetics , Thyroid Cancer, Papillary/etiology , Thyroid Cancer, Papillary/genetics , Thyroid Neoplasms/etiology , Thyroid Neoplasms/genetics , Adolescent , Adult , Child , Child, Preschool , DNA Copy Number Variations , Epigenome , Female , Gene Expression Profiling , Genes, ras , Genetic Variation , Humans , Infant , Iodine Radioisotopes , Loss of Heterozygosity , Male , Middle Aged , Proto-Oncogene Proteins B-raf/genetics , RNA-Seq , Radiation Dosage , Thyroid Gland/physiology , Thyroid Gland/radiation effects , Translocation, Genetic , Ukraine , Whole Genome Sequencing , Young Adult
16.
Thyroid ; 31(9): 1291-1296, 2021 09.
Article in English | MEDLINE | ID: mdl-33849309

ABSTRACT

Background: In 2013, the American Thyroid Association (ATA) issued a "Policy Statement on Thyroid Shielding During Diagnostic Medical and Dental Radiology." The recently updated National Council on Radiation Protection and Measurement Radiation Protection in Dentistry and Oral and Maxillofacial Imaging (NCRP Report No. 177) prompts this review of progress related to patient thyroid shielding since the ATA statement was published. Summary: Relevant publications appearing since the ATA statement were identified by querying PubMed for "thyroid and dental and (collar or shielding)" and substituting specific dental radiographic procedures in the search. The search was expanded by reviewing the cited papers in the PubMed-retrieved papers and by use of the Web of Science to retrieve papers citing the PubMed retrieved publications. Although many quantitative studies have appeared reflective of current dental radiographic instrumentation and practice, much more can be done to foster minimizing radiation to the thyroid. Conclusions: We list seven areas that should be pursued. Among them are harmonizing guidelines for the use of thyroid collars based on the recent studies and a comprehensive survey of current dental radiological practice patterns.


Subject(s)
Protective Devices , Radiation Exposure/adverse effects , Radiation Exposure/prevention & control , Radiation Injuries/prevention & control , Radiation Protection/instrumentation , Radiography, Dental/adverse effects , Thyroid Gland/radiation effects , Equipment Design , Humans , Lead , Practice Guidelines as Topic , Protective Devices/standards , Radiation Dosage , Radiation Injuries/etiology , Radiation Protection/standards , Radiography, Dental/standards , Risk Assessment , Risk Factors
17.
Cancer Epidemiol Biomarkers Prev ; 30(6): 1208-1217, 2021 06.
Article in English | MEDLINE | ID: mdl-33827984

ABSTRACT

BACKGROUND: Given the increased use and diversity of diagnostic procedures, it is important to understand genetic susceptibility to radiation-induced thyroid cancer. METHODS: On the basis of self-declared diagnostic radiology examination records in addition to existing literature, we estimated the radiation dose delivered to the thyroid gland from diagnostic procedures during childhood and adulthood in two case-control studies conducted in France. A total of 1,071 differentiated thyroid cancer (DTC) cases and 1,188 controls from the combined studies were genotyped using a custom-made Illumina OncoArray DNA chip. We focused our analysis on variants in genes involved in DNA damage response and repair pathways, representing a total of 5,817 SNPs in 571 genes. We estimated the OR per milli-Gray (OR/mGy) of the radiation dose delivered to the thyroid gland using conditional logistic regression. We then used an unconditional logistic regression model to assess the association between DNA repair gene variants and DTC risk. We performed a meta-analysis of the two studies. RESULTS: The OR/mGy was 1.02 (95% confidence interval, 1.00-1.03). We found significant associations between DTC and rs7164173 in CHD2 (P = 5.79 × 10-5), rs6067822 in NFATc2 (P = 9.26 × 10-5), rs1059394 and rs699517 both in ENOSF1/THYS, rs12702628 in RPA3, and an interaction between rs7068306 in MGMT and thyroid radiation doses (P = 3.40 × 10-4). CONCLUSIONS: Our results suggest a role for variants in CDH2, NFATc2, ENOSF1/THYS, RPA3, and MGMT in DTC risk. IMPACT: CDH2, NFATc2, ENOSF1/THYS, and RPA3 have not previously been shown to be associated with DTC risk.


Subject(s)
Biomarkers, Tumor/genetics , DNA Repair/radiation effects , Neoplasms, Radiation-Induced/epidemiology , Thyroid Gland/radiation effects , Thyroid Neoplasms/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Child , Dose-Response Relationship, Radiation , Female , France/epidemiology , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Neoplasms, Radiation-Induced/genetics , Polymorphism, Single Nucleotide , Risk Assessment/statistics & numerical data , Thyroid Gland/pathology , Thyroid Neoplasms/genetics , Thyroid Neoplasms/pathology , Young Adult
18.
Front Endocrinol (Lausanne) ; 12: 634955, 2021.
Article in English | MEDLINE | ID: mdl-33776929

ABSTRACT

Radioactive iodine is commonly used for the treatment of different thyroid conditions since the 1940s. The EANM has developed a standard pre-therapeutic procedure to estimate patient specific thyroid uptake at treatment of benign thyroid diseases. The procedure which models the time dependent fractional thyroid uptake is based on a two-compartment fitting system, one representing the thyroid and the other the blood. The absorbed dose is however only estimated for the thyroid and not for any other organ in the body. A more detailed biokinetic model for iodine is given by the ICRP and includes an iodide transport in the whole body. The ICRP model has 30 different compartments and 48 transfer coefficients to model the biokinetics of iodide and to model different transfer for inorganic iodide and organic iodine. The ICRP model is a recirculation iodine model, and the optimization is performed on the whole model and not exclusively on the thyroid as in the EANM procedure. Combining the EANM method and the ICRP model gives both patient specific estimations of thyroid uptake and retention and include most organs in the body. The new software gives both an improved patient specific dosimetry for the thyroid and an estimation of the absorbed dose to non-target organs and tissues like kidneys, urinary bladder, stomach wall, and uterus. Using the method described in this paper, the repercussions on the daily routines will be minimal.


Subject(s)
Iodine Radioisotopes/pharmacology , Radiometry/methods , Radiometry/standards , Thyroid Diseases/radiotherapy , Thyroid Neoplasms/radiotherapy , Algorithms , Female , Graves Disease/radiotherapy , Humans , Hyperthyroidism/radiotherapy , Hypothyroidism/radiotherapy , Iodine , Kinetics , Male , Radiation Dosage , Radiotherapy Planning, Computer-Assisted , Software , Thyroid Gland/radiation effects
19.
West Indian med. j ; 69(1): 51-55, 2021. tab, graf
Article in English | LILACS | ID: biblio-1341870

ABSTRACT

ABSTRACT Objective: To reveal the effect of 2100 MHz radio frequency (RF) radiation on thyroid tissues of rats in the 10 days (group E1) and 40 days (group G1) exposure groups. Methods: In this study, 30 healthy female Wistar albino rats, weighing 200−256 g each, were used. The animals were randomly divided into four groups (E1, E2, G1 and G2). Groups E2 and G2 served as the control groups. The exposure groups were exposed to 2100 MHz RF radiation emitted by a generator, simulating a 3G-mobile phone for 6 hours/day, 5 consecutive days/week, at the same time of the day (between 9 am and 3 pm), for 10 days (group E1) and 40 days (group G1). Results: Catalase and xanthine oxidase enzyme activities were compared between the groups E1 and E2; it was found that the difference was statistically significant (p < 0.05). Between the groups G1 and G2, the difference was found to be significant with respect to catalase activities. Tissue samples of the early and late groups showed no serious pathological findings in the histopathological examination. Conclusion: We believe that comprehensive, clinical and experimental studies are needed to assess the effect of the RF exposure duration and dosage of exposure on thyroid tissues.


Subject(s)
Animals , Female , Rats , Radiation Dosage , Thyroid Gland/radiation effects , Abnormalities, Radiation-Induced , Rats, Wistar , Models, Animal
20.
Laryngoscope ; 131(7): E2413-E2419, 2021 07.
Article in English | MEDLINE | ID: mdl-33609046

ABSTRACT

OBJECTIVES/HYPOTHESIS: Hypothyroidism is a relatively common complication of head and neck squamous cell carcinoma (HNSCC) treatment. The objective of this study was to determine whether the addition of programmed death ligand-1 (PD-1) or programmed death ligand-1 (PD-L1) inhibition (anti-PD-1/PD-L1 therapy) to standard treatment increases the risk of hypothyroidism in HNSCC. STUDY DESIGN: Retrospective Cohort. METHODS: This is a retrospective, single institutional cohort study. Patients who received radiotherapy (RT) for HNSCC were identified in the electronic medical record. Patient factors collected include age, sex, body mass index (BMI), smoking status, alcohol use, Charlson comorbidity index, and HNSCC treatment records. The rate of hypothyroidism for patients with HNSCC receiving RT (+/- chemotherapy and surgery) (RT group, n = 101) was compared to that of HNSCC patients receiving RT (+/- chemotherapy and surgery) + anti-PD-1/PD-L1 therapy, either concurrently or after RT (RT + anti-PD-1/PD-L1 group, n = 38). RESULTS: There was no significant difference in the rate of clinical or subclinical hypothyroidism between the two groups. Multinomial logistic regression found no significant difference in hypothyroidism based on age, sex, or BMI. CONCLUSIONS: The addition of anti-PD-1/PD-L1 therapy to standard HNSCC treatment does not significantly increase the risk of developing hypothyroidism. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E2413-E2419, 2021.


Subject(s)
Chemoradiotherapy, Adjuvant/adverse effects , Head and Neck Neoplasms/therapy , Hypothyroidism/epidemiology , Immune Checkpoint Inhibitors/adverse effects , Squamous Cell Carcinoma of Head and Neck/therapy , B7-H1 Antigen/antagonists & inhibitors , Chemoradiotherapy, Adjuvant/methods , Female , Follow-Up Studies , Humans , Hypothyroidism/etiology , Incidence , Male , Middle Aged , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Retrospective Studies , Risk Assessment/statistics & numerical data , Thyroid Gland/drug effects , Thyroid Gland/radiation effects
SELECTION OF CITATIONS
SEARCH DETAIL
...